Ample evidence implicates neuroinflammatory processes in the etiology and progression of Alzheimer’s disease (AD). To assess the specific role of the pro-inflammatory cytokine interleukin-1 (IL-1) in AD we examined the effects of intra-hippocampal transplantation of neural precursor cells (NPCs) with transgenic over-expression of IL-1 receptor antagonist (IL-1raTG) on memory functioning and neurogenesis in a murine model of AD (Tg2576 mice). WT NPCs- or sham-transplanted Tg2576 mice, as well as naive Tg2576 and WT mice served as controls. To assess the net effect of IL-1 blockade (not in the context of NPCs transplantation), we also examined the effects of chronic (4 weeks) intra-cerebroventricular (i.c.v.) administration of IL-1ra. We report that 12-month-old Tg2576 mice exhibited increased mRNA expression of hippocampal IL-1β, along with severe disturbances in hippocampal-dependent contextual and spatial memory as well as in neurogenesis. Transplantation of IL-1raTG NPCs 1 month before the neurobehavioral testing completely rescued these disturbances and significantly increased the number of endogenous hippocampal cells expressing the plasticity-related molecule BDNF. Similar, but less-robust effects were also produced by transplantation of WT NPCs and by i.c.v. IL-1ra administration. NPCs transplantation produced alterations in hippocampal plaque formation and microglial status, which were not clearly correlated with the cognitive effects of this procedure. The results indicate that elevated levels of hippocampal IL-1 are causally related to some AD-associated memory disturbances, and provide the first example for the potential use of genetically manipulated NPCs with anti-inflammatory properties in the treatment of AD.
Over the last two decades it became evident that inflammatory processes in the brain, including activation of microglia and production of pro-inflammatory cytokines, have an important role in the etiology and progression of Alzheimer’s disease (AD) (Akiyama et al, 2000; Glass et al, 2010; Heneka et al, 2010b; McGeer and McGeer, 2003). Over-production of the pro-inflammatory cytokine interleukin (IL)-1 has been particularly implicated in the pathophysiology of AD, because IL-1 is involved in acute neurodegeneration (Allan et al, 2005); post-mortem brain tissues from patients suffering from AD (as well as Down syndrome individuals, which usually develop AD in middle age) show increased production of IL-1, as well as the enzyme that is required for its processing (Griffin, 2011; Griffin et al, 1989); several IL-1 gene polymorphisms are associated with increased risk of developing AD (Rainero et al, 2004); IL-1 stimulates the expression of amyloid precursor protein (APP) (Goldgaber et al, 1989; Sheng et al, 1996) and promotes the hyperphosphorylation of tau (Ghosh et al, 2013; Li et al, 2003); reduced cholinergic function in AD is in part due to over-activity of acetylcholinesterase, whose levels can be elevated by IL-1 (Li et al, 2000); the drugs that are clinically used for treatment of AD (acetylcholiesterase inhibitors) attenuate the production of pro-inflammatory cytokines, including peripheral and brain IL-1 (Pollak et al, 2005); the NLRP3 inflammasome and its associated enzyme caspase-1, which are responsible for IL-1 cleavage from its precursor protein, are over-expressed in the brains of AD patients; deficiency in the NLRP3/caspase-1 axis was found to completely rescue the memory impairments and other pathological symptoms in a mouse model of AD (Heneka et al, 2013), and finally, chronic peripheral administration of IL-1 receptor blocking antibody alleviated the neuroinflammation and neurobehavioral pathology in a transgenic model of AD (Kitazawa et al, 2011). While these phenomena suggest that elevated levels of IL-1 contribute to the pathophysiology of AD, recent studies surprisingly demonstrated that sustained transgenic IL-1 over-expression, as well as in vitro exposure to IL-1, lead to a reduction in amyloid pathology, mediated by enhancement of microglia-dependent plaque degradation (Ghosh et al, 2013; Shaftel et al, 2007; Tachida et al, 2008), with no evidence for IL-1-associated apoptosis of neurons or cholinergic axon degeneration (Matousek et al, 2012). Together, these findings suggest that IL-1 and neuroinflammation may produce both detrimental and beneficial effects on specific AD symptoms (Matousek et al, 2012; Shaftel et al, 2008).
In addition to its role in immunoregulation of inflammatory processes, IL-1 has a major role in neurobehavioral regulation (Goshen and Yirmiya, 2009b; McAfoose and Baune, 2009). In particular, at pathophysiological levels IL-1 can produce detrimental effects on hippocampal-dependent memory processes (Rachal Pugh et al, 2001; Yirmiya and Goshen, 2011), which may be related to its effects on several mechanisms of neural plasticity, including suppression of neurogenesis (Goshen et al, 2008; Koo and Duman, 2008; Wu et al, 2012) and the production of brain-derived neurotrophic factor (BDNF) (Barrientos et al, 2003; Barrientos et al, 2004; Tong et al, 2008).
To integrate the neuroinflammatory, neuropathological and neurobehavioral effects of IL-1 in AD, we examined the specific role of hippocampal IL-1 signaling in the memory and neurogenesis disturbances exhibited by mice with AD-like pathology (Tg2576 mice) (Hsiao et al, 1996), by using intra-hippocampal transplantation of neural precursor cells (NPCs) with transgenic over-expression of IL-1 receptor antagonist (IL-1raTG). This approach was chosen because in this genetic animal model of AD mice exhibit neuropathological changes along with memory disturbance despite lack of neurodegeneration (Irizarry et al, 1997), providing a unique opportunity to investigate AD-related changes in a brain environment that affects neurobehavioral functioning without tissue loss, as well as to devise therapeutic procedures for reversing AD-like symptoms by changing this environment. Furthermore, this approach allows to pinpoint the location of IL-1’s involvement in AD-associated memory deficits, as we have previously shown that IL-1ra secretion by the transplanted NPCs is restricted to the hippocampus (ie, it does not diffuse to other brain or peripheral locations), and can counteract the IL-1-mediated detrimental effects of chronic stress on hippocampal-dependent memory and neurogenesis (Ben Menachem-Zidon et al, 2008). It should be noted that previous research has already demonstrated beneficial effects of WT NPCs transplantation on AD-associated memory disturbances (Blurton-Jones et al, 2009), and therefore we hypothesized that the effects of IL-1ra secretion will synergize with the effects of the NPCs transplantation to produce a very effective treatment for the AD-like symptoms. To assess the net effect of IL-1 blockade (not in the context of NPCs transplantation) we also examined the cognitive and neurogenic effects of chronic intra-cerebroventricular (i.c.v.) administration of IL-1ra.
MATERIALS AND METHODS
Subjects were C3B6-Tg (APP695)3Dbo/J male mice, expressing the Mo/Hu APPSWE45 mutation (Tg2576 mice), and their littermate controls (originally obtained from Taconic Farms, USA, and bred in our laboratory). Mice were housed in an air-conditioned room (23±1 °C), with food and water ad libitum. The behavioral experiments were conducted during the first half of the dark phase of the 12-h light/dark cycle. Newborn IL-1raTG mice (with astrocyte-directed over-expression of the human IL-1ra gene under the control of the murine glial fibrillary acidic protein (GFAP) promoter (Lundkvist et al, 1999)) and their WT controls (C57BL/6XCBA strain, originally derived from the non-transgenic littermates of the transgenic offspring) were used as a source for NPCs. The experiments were approved by the Hebrew University Committee on Animal Care and Use.
RNA Isolation, cDNA Synthesis and Real-Time PCR
To examine the levels of hippocampal IL-1β in Tg2576 vs WT mice, total RNA was isolated by a commercial TriReagent (Sigma). The amount and quality of RNA was determined with the ND-1000 spectrophotometer (NanoDrop, Wilmington, DE). First-strand cDNA synthesis was carried out with Super Script II RNase H-reverse transcriptase (Invitrogen) using a random primer.
The mRNA expression of IL-1β was quantified in the ABI Prism 7700 sequence detection system (Applied Biosystems) by using Platinum SYBR Green qPCR SuperMix UDG with ROX (Invitrogen), following the instructions of the manufacturer. Quantitative calculations of IL-1β expression vs HPRT was performed using the ΔΔCT method.
Preparation of NPCs and Growth of Neurospheres
NPC spheres were prepared from newborn IL-1raTG or WT mice, as previously described (Ben Menachem-Zidon et al, 2008; Ben-Hur et al, 2003). Briefly, the hemispheres were dissected, followed by removal of the meninges. The tissue was minced, digested by trypsin for 20 min, and dissociated. Following suspension in N2 medium, 10 × 106 cells were plated in a T-75 uncoated flask and supplemented with 10 ng/ml FGF2 and 20 ng/ml EGF, added daily. After 5 days of growth, undifferentiated neurospheres were collected for transplantation.
Prior to transplantation, spheres were incubated with 25 μg/ml BrdU for 72 hr. Examination of the spheres in vitro (before transplantation) revealed that >95% of the cells incorporated BrdU, as we previously reported (Fainstein et al, 2013). The spheres (4000 spheres/4 μl N2 medium) were bilaterally transplanted into the hippocampus using a stereotaxic instrument. Coordinates of the injection site (in mm relative to Bregma) were as follows: AP −2.6, L ±1.4, DV −1.6. Injections were conducted using a 25-μl Hamilton syringe. After each injection, the needle was left in situ for 5 min before being retracted, to allow complete diffusion of the spheres. The spheres were transplanted into the hippocampus of 11-month-old mice and behavioral testing commenced 4 weeks later. Mice from the sham-operated group were similarly injected with 4 μl N2 medium only. At the end of the behavioral tests (ie, 5–6 weeks post transplantation), animals were perfused with PBS followed by 4% paraformaldehyde. Tissues were deep frozen in liquid nitrogen and serial 8 μm brain coronal frozen sections were cut for histological analyses. In this study the spheres were transplanted only in the Tg2576 mice, because in a previous study we found that a similar procedure of spheres transplantation (ie, from either IL-1raTG or WT newborns) in WT mice did not produce any significant effects on memory functioning and neurogenesis (Ben Menachem-Zidon et al, 2008).
Cell Lineage Characterization and Quantification of the Transplanted Cells In Vivo
The transplanted cells were detected by immunostaining for BrdU. Sections were incubated with 2 N HCl for 30 min at 37 °C, washed, and incubated with 3% normal goat serum (NGS) for 1 hr at room temperature (RT), followed by incubation with rat anti-BrdU (clone BU1/75 (ICR1), serotec, 1 : 200 dilution) for 48 h at 4 °C. A goat anti-rat IgG secondary antibody, conjugated to Alexa 555, was added for 50 min at RT. To determine the fate of the transplanted cells, sections were double-stained for BrdU and the astrocytic marker GFAP (rabbit anti-GFAP; 1 : 100) or the neuronal marker NeuN (mouse anti–neuronal nuclei; 1 : 50), followed by incubation with goat anti rabbit IgG or goat anti-mouse IgG secondary antibodies, respectively, and conjugated to Alexa 488 (Molecular Probes) for 50 min at RT. Images were captured using Nikon E-600 and Olympus FV-1000 confocal microscopes and cameras.
BrdU-labeled cells were counted on every sixth 8-μm coronal section, covering the dorsal dentate gyrus in its entire rostro-caudal extension. The total number of transplanted cells was extrapolated for the entire volume of the dentate gyrus (Kempermann et al, 1997). Differentiation of transplanted cells into astrocytes and neurons was determined by immunofluorescent staining for GFAP and NeuN in brains transplanted with BrdU-labeled neurospheres. As no BrdU-labeled cells were also stained for NeuN, quantitative analysis focused on astrocytes. The percentage of graft-derived cells that differentiated into astrocytes was determined by dividing the number of cells manifesting double labeling for BrdU and GFAP by the total number of BrdU-positive cells. All analyses were conducted by an experimenter who was blind with respect to the experimental and control groups.
Evaluation of Growth Factors Expression by Transplanted and Host Cells
In order to evaluate the expression of growth factors by NPCs in vivo, slices were double-stained with BrdU and either BDNF or IGF-1. Staining for BDNF was done on slices that were blocked with Background Buster (Innovex biosciences) for 30 min, followed by incubation with primary antibody diluted in 0.3% triton X-100 for 24 h in RT. Goat anti rabbit IgG conjugated to Alexa 488 was added to 1 h in RT. Staining for IGF-1 was carried on slices that were blocked with 20% NGS in 0.1% triton X-100 followed by incubation with primary antibody for 24 h in RT. Donkey anti-Goat conjugated to Alexa 488 was added for 1 h in RT. The percentage of graft-derived cells that express BDNF or IGF-1 was determined by dividing the number of cells manifesting double labeling for BrdU and BDNF or IGF-1 by the total number of BrdU-positive cells. To evaluate possible differences between the expression of BDNF by WT cells and IL-1raTG cells, slides with clear evidence of the transplant were stained with BDNF and the percentages of cells that express BDNF were assessed. In order to explore the possibility that NPCs transplantation induced expression of BDNF by the host tissue, slides of DG areas located far from the transplanted IL-1raTG and WT cells (ie, at least 48 μm away from the last section in which BrdU-labeled cells were identified and further away until the anterior and posterior ends of the DG) were stained with BDNF, and the number of endogenous cells expressing this neurotrophin (but not labeled with BrdU) was calculated in these areas. In parallel, slides from naive and sham-operated mice were also stained with BDNF and positive cells for this neurotrophin were counted in matching areas.
Evaluation of Neurogenesis Levels by Immunostaining to Doublecortin
Slices containing the dentate gyrus of the hippocampus were stained for doublecortin (DCX). Slices were fixed in methanol for 20 min in −20 °C, followed by blocking with 1% BSA in PBS, diluted in 0.1% triton X-100. The primary antibody, anti-DCX (1 : 500; Chemicon), was added for 24 h at 4 °C followed by incubation with the secondary antibody, biotin-conjugated donkey anti-guinea pig IgG, for 2 h at RT and then incubation with 488-conjugated streptavidin (Jackson Laboratories) for 2 h at RT. Counterstaining was done with DAPI.
Evaluation of Plaque Area in Transgenic Mice
Slides were stained with 0.05% thioflavin-S in 50% ethanol in the dark for 8 min. This step was followed by two quick washes with 80% ethanol and then incubation with high concentration of phosphate buffer at 4 °C for 30 min. Slides were washed with distilled water and cover-slipped. Plaque area was measured using image analysis software (Nikon NIS elements) in the entire dorsal hippocampal DG area and in the piriform cortex.
Assessment of Microglia Density and Markers Expression
To evaluate the number and morphology of microglia in all the experimental groups, slides were fixed with 2% PFA, followed by blocking with 3% NGS in 5% BSA. The primary antibody, rabbit anti Iba-1 (1 : 200; Abcam), was added for 24 h at 4 °C. The secondary antibody, goat anti rabbit IgG (Molecular Probes), was added for 1 h at RT. Numbers of Iba-1-positive cells were counted in the entire DG of both hemispheres and the density of microglia cells was calculated. In addition, the number of microglia associated with DG plaques was counted and the ratio of microglia/plaque area was calculated. Microglia were considered to be plaque-associated if the Iba-1 staining of their soma or processes overlapped or was in clear contact with the thioflavin-S labeled plaque. Counting was conducted by an experimenter who was blind with respect to group assignment.
To further characterize the microglia phenotype, slides were blocked with goat serum and incubated overnight at 4 °C with anti-MHC-II (1 : 50; Chemicon). Secondary goat anti-mouse antibody was added for 1 h in RT. For TNFα staining, slides were fixated in methanol, dried and blocked with 2% BSA. Anti-TNFα (1 : 100; Abcam) was added for 24 h at 4 °C. Secondary donkey anti-goat antibody (Molecular Probes) was added for 1 h at RT. For IL-10 staining, slides were blocked with goat serum, incubated with goat anti-mouse IL-10 antibody (1 : 40; R&D Systems, Minneapolis, MN), washed, and incubated with the secondary donkey anti-goat antibody (Molecular Probes). All slides were counterstained with DAPI.
Intra-Cerebral IL-1ra Administration
Eleven-month-old Tg2576 and control mice were anesthetized with halothane and placed in a stereotaxic instrument. A burr hole was drilled through the skull over the lateral ventricle, 1.5 mm lateral to the midline and in a distance posterior to bregma that was computed by the formula (−0.4–0.66 × (bl−3.8)) mm, where bl is the distance between bregma and lambda. A 30-gauge Alzet brain infusion cannula was inserted into the lateral ventricle (3.2 mm from the skull surface), which was then cemented to three anchoring screws on the skull. A 4-week delivery Alzet osmotic minipump, filled with either IL-1ra (10 μg/day, Amgen, CA) or vehicle (Amgen, CA), was inserted into a subcutaneous pocket in the midscapular area of the back of the mouse, connected via a catheter to the brain cannula. The osmotic minipumps were replaced 2 weeks following their insertion with freshly filled minipumps (because in preliminary experiments we found that 2 weeks is the maximal time that IL-1ra will remain effective within these pumps). At 22–28 days after the initiation of IL-1ra treatment, mice were tested in the fear-conditioning and water maze paradigms (the testing order was counterbalanced, so half of the mice were first tested in the fear conditioning and then in the water maze and the order was reversed for the other half of the animals) and then killed for the assessment of histological and histopathological parameters.
Measurement of Learning and Memory in the Fear-Conditioning Paradigm
The fear-conditioning apparatus consisted of a transparent square conditioning cage (25 × 21 × 18 cm), with a grid floor wired to a shock generator and scrambler (Kinder scientific, U.S.). Mice were placed in the cage for 120 s, and then a pure tone (2.9 kHz) was sound for 20 s, followed by a 2-s, 0.5-mA foot-shock. This procedure was then repeated, and 30 s after the delivery of the second shock mice were returned to their home cage. Forty-eight hours later, fear conditioning was assessed by measuring the time spent in freezing (complete immobility) during exposure to the conditioned stimuli (ie, either the context or the tone), using an automated system (Kinder scientific, USA). The mice tested for contextual fear conditioning were placed in the original conditioning cage, and freezing was measured for 5 min. The mice tested for the auditory-cued fear conditioning were placed in a different context—a triangular-shaped cage with no grid floor. As a control for the influence of the novel environment, freezing was measured for 2.5 min in this new cage, and then the tone was sounded for 2.5 min, during which conditioned freezing was measured. Freezing was also measured during the first 120 s of the conditioning trial, before the tone and shock administration, in order to assess possible strain differences in baseline freezing.
Measurement of Learning and Memory in the Water Maze
Animals were trained in a circular pool (160 cm in diameter) filled with 23±2 °C water mixed with non-toxic gouache paint to make it opaque. In the spatial memory experiment, mice were trained to find the location of a hidden platform, submerged 1 cm below the water surface, using extra maze visual cues. Training consisted of three trials per day, with a 1-h break between trials, for 3 days using a random protocol, in which the entrance point to the maze was varied randomly between trials, and the platform remained in a permanent position. One day following training (ie, on the fourth experimental day) a probe trial was conducted, in which the platform was removed, the mice were placed in the water maze for 60 s, and the number of crossings over the previous location of the platform was recorded. A video camera above the pool was connected to a computerized tracking system (VP118 tracking system, HVS Image, Hampton, England), which monitored the latency to reach the platform in each training trial and the crossings over the platform in the probe trial (refre to studies by Avital et al (2003) and Goshen et al (2009a) for additional details).
The results were analyzed by one- or two-way ANOVAs, followed by the Tukey HSD post hoc analysis, when appropriate. The results of the water maze test were analyzed by three-way ANOVAs, with the trials as a repeated-measures factor.
Age of Memory Disturbances Onset in Tg2576 Mice
Previous studies on the age of onset of memory disturbances exhibited by Tg2576 mice reported inconsistent findings, and the effect of age on hippocampal neurogenesis impairments in Tg2576 mice has not been systematically determined. Therefore, we first examined memory functioning and neurogenesis in different age groups of Tg2576 and WT control mice. At 3, 6 and 9 months of age, contextual fear-conditioning memory in Tg2576 mice was similar to their littermate controls, whereas at 12 months of age Tg2576 mice displayed significantly impaired fear conditioning, compared with all other age groups (F(3,11)=178.1, P<0.001) (Figure 1a). In the Morris water maze paradigm, 12-month-old Tg2576 mice also displayed a significant spatial learning impairment compared with their littermate controls (F(3,11)=2.916, P=0.006) (Figure 1b). The latency to reach the platform was not influenced by changed motivation or motor performance because there were no differences in the swimming speed among the groups (P>0.5). At a young age (3 months) there was no difference in hippocampal neurogenesis between Tg2576 mice and their controls; however, at 12 months of age Tg2576 mice displayed markedly reduced neurogenesis. These findings were reflected by a significant strain by age interaction (F(3,1)=24.235, P<0.001) (Figure 1c). Similarly, whereas at 3 months of age there was no difference in the levels of hippocampal IL-1β mRNA expression between Tg2576 mice and their littermate controls, at 12 months of age Tg2576 mice displayed markedly elevated IL-1β mRNA expression, reflected by a significant strain by age interaction (F(3,11)=170.17, P<0.001) (Figure 1d).
Effects of NPCs Transplantation on Memory Functioning in the Fear Conditioning and Water Maze Paradigms
Memory functioning was assessed in 12-month-old WT naive (untreated) mice and four groups of Tg2576 mice (naive, sham-operated, and transplanted with either WT or IL-1raTG NPCs at 11 months of age). In the contextual fear-conditioning paradigm, naive and sham-operated Tg2576 mice exhibited markedly impaired contextual fear-conditioning memory, as compared with naive WT mice. Transplantation with either WT or IL-1raTG NPCs completely reversed this memory impairment (Figure 2a), as reflected by a significant overall difference among the groups (F(4,24)=6.456, P<0.05).
In the water maze paradigm, naive and sham-operated Tg2576 mice displayed severely impaired spatial learning and memory, with almost no reductions in the latencies to reach the hidden platform over the entire training period. WT NPCs-transplanted Tg2576 mice also showed marked learning impairment, with limited improvement over trials, but IL-1raTG NPCs-transplanted Tg2576 mice were completely rescued from this impairment, displaying reductions in the latency to reach the hidden platform that were similar to those of WT controls (Figure 2b). These findings were reflected by a significant group by trials interaction (F(4,38)=3.990, P<0.05). The latency to reach the platform was probably not influenced by changes in motivation or motor performance because there were no differences in the swimming speed among the groups (average velocity=18.6–20.3 cm/s; P>0.5). To further elucidate these differences, an additional analysis was conducted, comparing the latencies to reach the platform on the last day of training (Figure 2c), demonstrating significant overall difference among the groups (F(4,38)=5.059, P<0.05), with complete reversal of the memory impairment in IL-1raTG NPCs-transplanted mice (as compared with naive and sham mice) and partial reversal in WT NPCs-transplanted mice (which were not different from either naive and sham-operated mice or from IL-1raTG NPCs-transplanted mice). In the probe trial, comparison of the number of crossings over the previous location of the platform showed a significant difference between the groups (F(4,23)=10.596, P<0.01), with complete rescue of the memory impairment in IL-1raTG NPCs-transplanted Tg2576 mice, which were significantly different from all other groups of Tg2576 mice and not different from the WT mice (Figure 2d).
Localization and Characterization of the Transplanted NPCs
The distribution and differentiation of transplanted NPCs within the host brain were examined after completion of all behavioral tests (ie, 5–6 weeks post transplantation). NPCs were labeled with BrdU before transplantation and could be clearly detected in the host dentate gyrus (DG) area (including the hilus, granular and molecular layers) (Figure 3a). The average numbers (±SEM) of WT and IL-1raTG BrdU-labeled cells in the DG of the Tg2576 mice were 8088 ±318 and 8043 ±341, respectively. To evaluate the pattern of differentiation of the transplanted NPCs, slides were double-stained for BrdU, together with glial or neuronal markers. Immunohistochemistry and quantification of double-labeled cells revealed that 78% of the BrdU-labeled cells expressed the astrocytic marker GFAP (Figures 3a and b). In contrast, no double-staining for BrdU and the neuronal marker NeuN was observed in any cell (data not shown). This pattern of differentiation was evident for either WT- or IL-1raTG-transplanted cells. To further characterize the transplanted cells, slides were double-stained for BrdU and the neurotrophic factors BDNF and IGF-1. The percentages of cells that expressed these markers were calculated among the BrdU-positive cells, showing that 85% of the transplanted cells expressed BDNF (Figure 3c) and 72% of the cells expressed IGF-1 (Figure 3d), with no discernible differences between WT and IL-1raTG NPCs. Most of the NPCs obtained from IL-1raTG mice (but none from WT mice) expressed hIL-1ra (Figure 3e).
Effects of NPCs Transplantation on Hippocampal Neurogenesis and BDNF Expression
As a first attempt to explore possible mechanisms that underlie the effects of NPCs transplantation on learning and memory functioning we assessed the number of adult-born neurons (doublecortin (DCX)-labeled) and BDNF-expressing cells in the dentate gyrus of the hippocampus. Immunohistochemistry for DCX revealed a significant difference among the groups (F(4,98)=15.656; P<0.0001) (Figures 4a and c and d). Specifically, both naive and sham-operated Tg2576 mice displayed suppressed hippocampal neurogenesis, compared with the WT naive group, and this effect was completely rescued in Tg2576 mice transplanted with either WT or IL-1raTG NPCs. It should be noted that NPCs transplantation affected neurogenesis from endogenous stem cells/NPCs, as the exogenously transplanted NPCs did not express DCX. Analysis of the number of BDNF-expressing endogenous cells (ie, measured in hippocampal areas not containing BrdU-labeled transplanted NPCs) also revealed a significant difference among the groups (F(4,193)=39.938, P<0.001) (Figures 4b). Specifically, Tg2576 mice transplanted with WT NPCs displayed greater number of BDNF-positive endogenous cells than WT mice, and IL-1raTG NPCs-transplanted mice showed significantly higher number of BDNF-positive cells than all other groups.
Effects of NPCs Transplantation on Plaque Area and Microglial Density and Phenotype
As the formation of amyloid plaques constitutes the neuropathological hallmark of AD and may be involved in the neurobehavioral alterations in Tg2576 mice, we used thioflavin staining to evaluate the area covered by plaques in the DG, as well as in the piriform cortex, which is particularly prone to the development of plaques in AD (Kim et al, 2012). A significant difference in DG plaque area was found between the Tg2576 groups (F(3,8)=96705.193, P<0.001) (Figures 5a–c). Specifically, sham-operated Tg2576 mice displayed a dramatic increase in plaque area, as compared with naive mice, whereas both WT and IL-1raTG NPCs transplantation significantly reduced the operation-related increase in plaque area, although plaque area in these groups was still significantly larger than in naive mice. Plaque area in the piriform cortex also differed among the groups (F(3,8)=101. 449, P<0.001) (Figure 5d), but in this case all operated groups (sham-operated or transplanted with either WT or IL-1raTG NPCs) displayed greater plaque area than the naive group.
Microglia, which are responsible for most (but not all) production of brain IL-1, have key roles in the formation and degradation of plaques in AD (Farfara et al, 2008; Lynch, 2009; Weitz and Town, 2012), and may be also involved in cognitive functioning and neurogenesis (Blank and Prinz, 2013; Ekdahl et al, 2009; Yirmiya and Goshen, 2011). Therefore, we assessed the density of microglia in the hippocampal DG and piriform cortex, as well as the number of microglia specifically associated with plaques. Significant group differences were found in DG microglial density (number of microglia/DG area) (Figure 5e) (F (4,48)=6.368.P<0.001). Specifically, transplantation of either WT or IL-1raTG NPCs significantly increased microglia density, as compared with all other groups. Particularly, high density of microglia was observed in association with the plaques (Figure 5f), with significant differences among the groups (F(3,45)=20.615, P<0.001), stemming from increased number of microglia/plaque area in mice transplanted with either WT or IL-1raTG NPCs, as compared with naive and sham-operated mice (Figures 5g and h). Plaque-associated microglia in all groups displayed activated morphology (round cell bodies with reduced processes ramification) and some microglia were shown to extend processes into the plaque area (Figures 5g and h). As a first attempt to characterize the phenotype and polarization of the plaque-associated microglia, immunostainings for the M1-associated markers MHCII and TNFα, as well as the M2-associated marker IL-10 were conducted. In all groups ∼20% of the microglia expressed MHC-II (Figure 5i), but almost no expression of TNFα was observed. Importantly, although in naive and sham-operated mice no cells were found to express the anti-inflammatory cytokine interleukin-10, in the WT and IL-1raTG NPCs-transplanted groups almost all cells around the plaques were positive for this cytokine (Figure 5j), suggesting a shift towards an alternative (M2) microglial phenotype. Analysis of microglial density and the number of microglia specifically associated with plaques in the piriform cortex revealed no parallel group differences, ie, the microglial density and the number of microglia per plaque were overall similar to those measured in the DG of naive and sham-operated mice, and there were no increases in these parameters by NPCs transplantation (Figures 5k and l).
Effects of Chronic IL-1ra Administration on Memory Functioning, Neurogenesis, BDNF Expression, Plaque Area and Microglial Density
To examine the net effect of IL-1 blockade (ie, not in the context of the NPCs transplantation) we studied the effects of chronic i.c.v. administration of hIL-1ra, using the same paradigms and timing employed in the experiment on NPCs transplantation. The chronic administration of hIL-1ra resulted in high levels of this cytokine in the hippocampus, as compared with almost no IL-1ra in vehicle-treated mice hippocampus (t(5)=5.64, P<0.001) (Figure 6a). In the fear-conditioning paradigm, Tg2576 mice displayed a significant memory impairment, which was not prevented by the IL-1ra treatment, as reflected by a significant strain effect (F(3,22)=10.761, P<0.05) (Figure 6b). In the water maze paradigm, vehicle-treated Tg2576 mice displayed a severe learning and memory impairment, with no improvement in the latency to reach the hidden platform over the entire training period, but in contrast with the result in the fear-conditioning task this impairment was completely rescued by the IL-1ra treatment, equating the performance of the treated Tg2576 mice to that of the WT groups. This finding was reflected by a strain by treatment by trials interaction (F(3,24)=5.906, P<0.05) (Figure 6c). The latency to reach the platform was not influenced by changed motivation or motor performance because there were no differences in the swimming speed between the groups (P>0.5). Spatial memory was further assessed by a probe trial 1 day following the completion of the 3-day training by placing the mice in the water maze without the platform and measuring the number of passes over the former location of the platform. Vehicle-treated Tg2576 mice displayed a marked impairment in this task, which was completely reversed by IL-1ra treatment, reflected by a significant strain by treatment interaction (F(3,24)=4.32. P<0.05) (Figure 6d).
At the completion of the behavioral tests, mice were perfused and the levels of DG neurogenesis and BDNF expression were examined. Vehicle-administered Tg2576 mice exhibited significantly reduced level of neurogenesis, compared with WT mice (injected with either saline or IL-1ra) and this reduction was significantly (although not completely) prevented by IL-1ra administration. These findings were reflected by a significant strain by treatment interaction (F(3,21)=6.19, P<0.05) (Figure 6e). The IL-1ra treatment induced significant elevations in the number of BDNF-expressing cells in both WT and Tg2576 mice (F (1,18)=5.803, P<0.05) (Figure 6f). IL-1ra treatment produced no effects on DG plaque area (Figure 6g) or microglial density (Figure 6h) (P>0.1). The number of plaque-associated microglia was significantly reduced in IL-1ra-treated mice (t(6)=11.53, P<0.001) (Figure 6i).
The results of this study show that intra-hippocampal transplantation of NPCs with transgenic over-expression of IL-1ra can rescue the cognitive disturbances exhibited by mice with AD-like pathology and increase the production of the plasticity-related molecule BDNF. Similar, but less-consistent effects were also produced by transplantation of WT NPCs as well as by blockade of IL-1 signaling using chronic intra-cerebral administration of IL-1ra. Furthermore, the present findings demonstrate for the first time that transplantation of either WT or IL-1raTG NPCs can rescue the severe impairment in hippocampal neurogenesis displayed by AD-like mice, and that a similar, albeit more partial amelioration of the neurogenesis deficit can be produced by pharmacological blockade of brain IL-1 signaling.
As currently approved drugs for AD provide limited long-term benefits, and the development of novel drugs that target Aβ or tau pathology has been slow and frustrating, it has been suggested that stem cell transplantation could offer a promising therapeutic approach to AD (Chen and Blurton-Jones, 2012). In some neurological diseases the transplantation of stem cells or their differentiated derivatives, such as NPCs, can cause functional improvement by replacing lost cell, particularly neurons. However, in AD, in which the impairments in neuronal systems, synaptic connectivity and neurochemical functionality are widespread, it is more likely that stem cells will be efficacious via the secretion of trophic factors that influence the endogenous cells or via their anti-inflammatory activity (Chen and Blurton-Jones, 2012; De Feo et al, 2012). The present study are in agreement with the findings of a previous study, demonstrating that WT NPCs ameliorate the cognitive disturbances in triple transgenic mice (3 × Tg-AD) that express pathogenic forms of amyloid precursor protein, presenilin, and tau (Blurton-Jones et al, 2009), and together these studies support the notion that NPCs transplantation indeed has promising effects on AD-induced impairments in learning, memory and neuroplasticity, mediated by the secretion of compounds that block endogenous disruptors of these processes (such as IL-1) and compounds that promote these processes (such as BDNF), as detailed below.
The results of the present study corroborate our previous demonstrations (Ben Menachem-Zidon et al, 2011; Ben Menachem-Zidon et al, 2008) that transplanted WT and IL-1raTG NPCs readily survive in the host hippocampus for many weeks and differentiate mainly into astrocytes (in a preliminary experiment we found that the transplanted cells can survive for >9 months post transplantation). In a previous report (Ben Menachem-Zidon et al, 2008), we showed that the transplanted IL-1raTG NPCs dramatically increase the levels of IL-1ra in the hippocampus, but not in other regions of the brain. In the AD-like mice this elevation was functionally important for spatial memory, because this type of memory was markedly improved only by transplantation of IL-1raTG NPCs, whereas contextual fear-conditioning memory and neurogenesis were improved by transplantation of both WT and IL-1raTG NPCs. This pattern of results suggests (but does not prove) that transplantation-induced neurogenesis facilitation may account for the improvement in contextual memory, which is more dependent on neurogenesis than spatial memory (Hernández-Rabaza et al, 2009; Meshi et al, 2006), whereas the effect of IL-1 blockade in the water maze task is probably mediated by another process (eg, the enhanced BDNF production).
This conclusion is validated by the present findings that i.c.v. administration of IL-1ra (which elevated hippocampal IL-1ra levels to those found in IL-1raTG NPCs-transplanted mice) beneficially affected spatial memory but not fear conditioning, suggesting a specific sensitivity of spatial memory to disruption by IL-1 in AD context, which has not been reported hereto. The current finding of beneficial effects of IL-1 signaling blockade extends our previous report that transplantation of IL-1raTG NPCs ameliorate the cognitive and neurogenic impairments induced by chronic stress (Ben Menachem-Zidon et al, 2008), as well as the recently reported beneficial cognitive effects of IL-1 blockade in 3 × Tg-AD mice (Kitazawa et al, 2011). In the latter study, IL-1 signaling was blocked by peripheral administration of anti-IL-1R blocking monoclonal antibodies, but as no such antibodies were found within the brain, the localization of these effects (peripheral vs central) remained uncertain. The present results, demonstrating increased IL-1β mRNA expression in the hippocampus of aging Tg2576 mice, and rescue of the AD-associated hippocampal-dependent spatial memory impairment by NPCs that secrete IL-1ra specifically in this structure, indicate that the effects of IL-1 blockade occur directly within the hippocampus.
The effects of WT and IL-1raTG NPCs transplantation may be mediated by several mechanisms, including increases in hippocampal neurogenesis and BDNF production, as well as reductions in plaque burden and alterations in microglia status. Mounting evidence indicates that transgenic models of AD are associated with impairments in hippocampal neurogenesis, which may at least partially underlie the cognitive disturbances exhibited in such models (Mu and Gage, 2011; Shruster et al, 2010). The results of the present study are the first to show that NPCs transplantation into the hippocampus of AD-like mice completely rescues their neurogenesis disturbances. Blockade of IL-1 signaling using IL-1ra administration also partially rescued the neurogenesis impairment, consistently with the known detrimental effects of elevated hippocampal IL-1 levels on neurogenesis and the ability of genetic, cellular and pharmacological IL-1 blockade procedures to prevent neurogenesis suppression in various conditions associated with elevated brain IL-1 levels (Ben Menachem-Zidon et al, 2008; Goshen et al, 2008; Koo and Duman, 2008).
In view of the critical role of neurotrophic factors, particularly BDNF, in memory, neural plasticity and neurogenesis, as well as findings that in brains of AD patients BDNF levels are decreased, dysregulation of neurotrophic activity was proposed as an important mechanism contributing to AD pathology (Nagahara and Tuszynski, 2011). Consistently, neurotrophin expression and secretion by various types of stem cells was proposed as an important mechanism for their ability to counteract cognitive and neuropathological symptoms of AD in transgenic models (Chen and Blurton-Jones, 2012). Indeed, a study using BDNF gain-of-function and loss-of-function demonstrated that the production of BDNF by transplanted NPCs is critical for their beneficial effects on cognitive functioning and synaptic plasticity (Blurton-Jones et al, 2009). The results of the present study demonstrate that in addition to the expression of BDNF by the transplanted NPCs, the transplantation induced a significant increase in the number of endogenous cells that express BDNF. Furthermore, the transgenic IL-1ra over-expression potentiated the NPCs-induced increases in BDNF expression, and treatment with IL-1ra was also capable of promoting BDNF expression by endogenous cells. These findings are consistent with the known suppressive effects of IL-1 on BDNF expression (Barrientos et al, 2003; Barrientos et al, 2004; Tong et al, 2008) and corroborate the possible role of elevated hippocampal BDNF levels in promoting functional recovery in AD.
Although the formation of amyloid plaques represents the hallmark pathological symptom of AD, the relationship between plaques and cognitive functioning is still intensely debated (Golde et al, 2011; Karran et al, 2011). In the present study, comparisons between naive and sham-operated Tg2576 mice revealed that the surgery (along with the halothane anesthesia, which was given only to the operated animals) produced a widespread increase in amyloid plaque area, in accordance with previous research demonstrating that both surgery and anesthesia can enhances amyloidopathy in AD-like mice (Lu et al, 2010; Tang et al, 2013). In contrast with its dramatic effect on amyloid plaques, surgery had no discernible effect on memory and neurogenesis. These findings dramatically demonstrate dissociation between plaque formation and neurobehavioral disturbances (at least in the early stage of the disease exhibited by the animals in this study). Interestingly, NPCs transplantation (either WT or IL-1raTG) significantly reduced the surgery-induced increase in plaque formation, whereas IL-1 blockade did not seem to affect plaque area (reflected by no difference between the effects of WT vs IL-1raTG NPCs transplantation and no effect of the IL-1ra infusion, consistently with a previous report of no effect of IL-1 blockade on APP levels (Oprica et al, 2007)). The effects of NPCs transplantation on plaque burden may be related to the increase in the overall density of microglia, and particularly the increase in the number of activated microglia associated with the plaques. The mechanism for this effect of the NPCs is not clear, but it may be suggested that the transplanted cells constitute an immune challenge that induces microglia proliferation and/or migration into the hippocampus, as well as promotion of their activation against the amyloid plaques. This conclusion is strengthened by the findings that the effects of NPCs transplantation on both plaque formation and plaque-associated microglial number were specific to the location of the transplantation, as they were evident in the DG but not the piriform cortex. As shown previously, microglia can effectively clear amyloid plaques (Lee and Landreth, 2010), and the recruitment of microglial with alternative (M2) morphology was specifically associated with improved phagocytic functioning (Medeiros et al, 2013). The morphological relations between microglia and plaques observed here, and the M2-like phenotype exhibited by these cells suggest the possibility of such a process in the current study. Previous studies indicated that IL-1 signaling can either interfere with (Heneka et al, 2013; Heneka et al, 2010a) or facilitate (Shaftel et al, 2008; Shaftel et al, 2007) microglia-mediated plaque degradation and phagocytosis. In the present study, pharmacological administration of IL-1ra was found to reduce the number of microglia associated with plaques, but this reduction was not associated with significant effects on plaque area. Thus, the relations between IL-1 signaling, microglial status and the formation and degradation of plaques should be further investigated.
In conclusion, the results of the present study demonstrate that hyper-secretion of IL-1 within the hippocampus contributes to AD-associated deficits in at least some forms of memory (particularly spatial memory). Furthermore, the present findings extend previous reports, demonstrating that transplantation of WT NPCs or long-term pharmacological IL-1 blockade can ameliorate AD-associated neurobehavioral deficits, by demonstrating that combination of these approaches exceeds the beneficial potential of each approach by itself. The idea that genetic manipulations before transplantation could enhance the therapeutic potential of NPCs, by turning them into ‘Trojan horses’ delivering specific proteins to the AD-afflicted brain, has been suggested (Chen and Blurton-Jones, 2012) but not tested so far. Our results provide the first example for the use of genetically manipulated NPCs in the treatment of AD, indicating that supplementation of NPCs therapy with the delivery of an anti-inflammatory agent, particularly IL-1ra, can potentiate the beneficial effects of NPCs transplantation on cognition, possibly by inducing the expression of BDNF by endogenous hippocampal cells.
FUNDING AND DISCLOSURE
The authors declare no conflict of interest.
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM et al (2000). Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383–421.
Allan SM, Tyrrell PJ, Rothwell NJ (2005). Interleukin-1 and neuronal injury. Nat Rev Immunol 5: 629–640.
Avital A, Goshen I, Kamsler A, Segal M, Iverfeldt K, Richter-Levin G et al (2003). Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus 13: 826–834.
Barrientos RM, Sprunger DB, Campeau S, Higgins EA, Watkins LR, Rudy JW et al (2003). Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 121: 847–853.
Barrientos RM, Sprunger DB, Campeau S, Watkins LR, Rudy JW, Maier SF (2004). BDNF mRNA expression in rat hippocampus following contextual learning is blocked by intrahippocampal IL-1beta administration. J Neuroimmunol 155: 119–126.
Ben Menachem-Zidon O, Avital A, Ben-Menahem Y, Goshen I, Kreisel T, Shmueli EM et al (2011). Astrocytes support hippocampal-dependent memory and long-term potentiation via interleukin-1 signaling. Brain Behav Immun 25: 1008–1016.
Ben Menachem-Zidon O, Goshen I, Kreisel T, Ben Menahem Y, Reinhartz E, Ben Hur T et al (2008). Intrahippocampal transplantation of transgenic neural precursor cells overexpressing interleukin-1 receptor antagonist blocks chronic isolation-induced impairment in memory and neurogenesis. Neuropsychopharmacology 33: 2251–2262.
Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrachi-Kol R, Grigoriadis N (2003). Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol Cell Neurosci 24: 623–631.
Blank T, Prinz M (2013). Microglia as modulators of cognition and neuropsychiatric disorders. Glia 61: 62–70.
Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, Muller FJ, Loring JF et al (2009). Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci USA 106: 13594–13599.
Chen WW, Blurton-Jones M (2012). Concise review: can stem cells be used to treat or model Alzheimer's disease? Stem Cells 30: 2612–2618.
De Feo D, Merlini A, Laterza C, Martino G (2012). Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr Opin Neurol 25: 322–333.
Ekdahl CT, Kokaia Z, Lindvall O (2009). Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158: 1021–1029.
Fainstein N, Einstein O, Cohen ME, Brill L, Lavon I, Ben-Hur T (2013). Time limited immunomodulatory functions of transplanted neural precursor cells. Glia 61: 140–149.
Farfara D, Lifshitz V, Frenkel D (2008). Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 12: 762–780.
Ghosh S, Wu MD, Shaftel SS, Kyrkanides S, LaFerla FM, Olschowka JA et al (2013). Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci 33: 5053–5064.
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934.
Golde TE, Schneider LS, Koo EH (2011). Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69: 203–213.
Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS et al (1989). Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86: 7606–7610.
Goshen I, Avital A, Kreisel T, Licht T, Segal M, Yirmiya R (2009a). Environmental enrichment restores memory functioning in mice with impaired IL-1 signaling via reinstatement of long-term potentiation and spine size enlargement. J Neurosci 29: 3395–3403.
Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T et al (2008). Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 13: 717–728.
Goshen I, Yirmiya R (2009b). Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 30: 30–45.
Griffin WS (2011). Alzheimer's—looking beyond plaques. F1000 Med Rep 3: 24.
Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ et al (1989). Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86: 7611–7615.
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A et al (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 493: 674–678.
Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D et al (2010a). Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107: 6058–6063.
Heneka MT, O'Banion MK, Terwel D, Kummer MP (2010b). Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117: 919–947.
Hernández-Rabaza V, Llorens-Martín M, Velázquez-Sánchez C, Ferragud A, Arcusa A, Gumus HG et al (2009). Inhibition of adult hippocampal neurogenesis disrupts contextual learning but spares spatial working memory, long-term conditional rule retention and spatial reversal. Neuroscience 159: 59–68.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S et al (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99–102.
Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997). APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965–973.
Karran E, Mercken M, De Strooper B (2011). The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10: 698–712.
Kempermann G, Kuhn HG, Gage FH (1997). Genetic influence on neurogenesis in the dentate gyrus of adult mice. Proc Natl Acad Sci USA 94: 10409–10414.
Kim TK, Lee JE, Park SK, Lee KW, Seo JS, Im JY et al (2012). Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1dE9 transgenic mouse models of Alzheimer disease. Exp Mol Med 44: 492–502.
Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V et al (2011). Blocking IL-1 Signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 187: 6539–6549.
Koo JW, Duman RS (2008). IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105: 751–756.
Lee CY, Landreth GE (2010). The role of microglia in amyloid clearance from the AD brain. J Neural Transm 117: 949–960.
Li Y, Liu L, Barger SW, Griffin WS (2003). Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J Neurosci 23: 1605–1611.
Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE et al (2000). Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 20: 149–155.
Lu Y, Wu X, Dong Y, Xu Z, Zhang Y, Xie Z (2010). Anesthetic sevoflurane causes neurotoxicity differently in neonatal naive and Alzheimer disease transgenic mice. Anesthesiology 112: 1404–1416.
Lundkvist J, Sundgren-Andersson AK, Tingsborg S, Ostlund P, Engfors C, Alheim K et al (1999). Acute-phase responses in transgenic mice with CNS overexpression of IL-1 receptor antagonist. Am J Physiol 276 (3 Pt 2): R644–R651.
Lynch MA (2009). The multifaceted profile of activated microglia. Mol Neurobiol 40: 139–156.
Matousek SB, Ghosh S, Shaftel SS, Kyrkanides S, Olschowka JA, O'Banion MK (2012). Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J Neuroimmune Pharmacol 7: 156–164.
McAfoose J, Baune BT (2009). Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 33: 355–366.
McGeer EG, McGeer PL (2003). Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27: 741–749.
Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs DH et al (2013). Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol 182: 1780–1789.
Meshi D, Drew MR, Saxe M, Ansorge MS, David D, Santarelli L et al (2006). Hippocampal neurogenesis is not required for behavioral effects of environmental enrichment. Nat Neurosci 9: 729–731.
Mu Y, Gage FH (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener 6: 85.
Nagahara AH, Tuszynski MH (2011). Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov 10: 209–219.
Oprica M, Hjorth E, Spulber S, Popescu BO, Ankarcrona M, Winblad B et al (2007). Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med 11: 810–825.
Pollak Y, Gilboa A, Ben-Menachem O, Ben-Hur T, Soreq H, Yirmiya R (2005). Acetylcholinesterase inhibitors reduce brain and blood interleukin-1beta production. Ann Neurol 57: 741–745.
Rachal Pugh C, Fleshner M, Watkins LR, Maier SF, Rudy JW (2001). The immune system and memory consolidation: a role for the cytokine IL-1beta. Neurosci Biobehav Rev 25: 29–41.
Rainero I, Bo M, Ferrero M, Valfre W, Vaula G, Pinessi L (2004). Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis. Neurobiol Aging 25: 1293–1298.
Shaftel SS, Griffin WS, O'Banion MK (2008). The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 5: 7.
Shaftel SS, Kyrkanides S, Olschowka JA, Miller JN, Johnson RE, O'Banion MK (2007). Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 117: 1595–1604.
Sheng JG, Ito K, Skinner RD, Mrak RE, Rovnaghi CR, Van Eldik LJ et al (1996). In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging 17: 761–766.
Shruster A, Melamed E, Offen D (2010). Neurogenesis in the aged and neurodegenerative brain. Apoptosis 15: 1415–1421.
Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y et al (2008). Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem 104: 1387–1393.
Tang JX, Mardini F, Janik LS, Garrity ST, Li RQ, Bachlani G et al (2013). Modulation of murine Alzheimer pathogenesis and behavior by surgery. Ann Surg 257: 439–448.
Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW (2008). Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 29: 1380–1393.
Weitz TM, Town T (2012). Microglia in Alzheimer's Disease: It's All About Context. Int J Alzheimers Dis 2012: 314185.
Wu MD, Hein AM, Moravan MJ, Shaftel SS, Olschowka JA, O'Banion MK (2012). Adult murine hippocampal neurogenesis is inhibited by sustained IL-1β and not rescued by voluntary running. Brain Behav Immun 26: 292–300.
Yirmiya R, Goshen I (2011). Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 25: 181–213.
This research was supported by The Legacy Heritage Bio-Medical Program of the Israel Science Foundation (grant no. 430/09), and in part by grants from the Alzheimer’s Drug Discovery Foundation (grant number 270804), the Israel Ministry of Health (grant number 2985) and Cure Alzheimer’s Fund. We thank Dr Mikhal Cohen, Sys Kochavi and Erez Yirmiya for help with specific technical aspects of the study.
Dr Ofra Ben Menachem-Zidon designed the work that led to the submission, acquired data, had an important role in interpreting the results, drafted the manuscript and approved the final version. Mr Yair Ben Menahem acquired data and approved the final version. Dr Tamir Ben-Hur had an important role in interpreting the results, revised the manuscript and approved the final version. Dr Raz Yirmiya conceived and designed the work that led to the submission, had an important role in interpreting the results, drafted the manuscript and approved the final version.
The corresponding author confirms that he has had full access to the data in the study and final responsibility for the decision to submit for publication.
Rights and permissions
About this article
Cite this article
Ben-Menachem-Zidon, O., Ben-Menahem, Y., Ben-Hur, T. et al. Intra-Hippocampal Transplantation of Neural Precursor Cells with Transgenic Over-Expression of IL-1 Receptor Antagonist Rescues Memory and Neurogenesis Impairments in an Alzheimer’s Disease Model. Neuropsychopharmacol 39, 401–414 (2014). https://doi.org/10.1038/npp.2013.208
- Alzheimer’s disease
- neural precursor cells
This article is cited by
Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis
Stem Cell Research & Therapy (2023)
Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
Molecular Biology Reports (2019)
Astrocytes decrease adult neurogenesis during virus-induced memory dysfunction via IL-1
Nature Immunology (2018)
Lentivirus-mediated interleukin-1β (IL-1β) knock-down in the hippocampus alleviates lipopolysaccharide (LPS)-induced memory deficits and anxiety- and depression-like behaviors in mice
Journal of Neuroinflammation (2017)
Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice
Inflammation Research (2017)